InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (4 ops.)
Insider track record
ExecutiveDisclosed buys
4
Disclosed sells
4
T+90 hit rate
100%
T+90 mean return
+14.9%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Hayes Christopher G., Directeur Juridique. Insider active across 1 company, notably Verrica Pharmaceuticals Inc.. In total, 12 disclosures have been logged. Split: 4 buys · 4 sells. Total volume traded: €343k. Activity tracked since 4 June 2021. The latest transaction was disclosed on 17 March 2025 (Cession). Regulator: SEC (Form 4). All data is free.
Declarations12 total
4,315 shares@ US$0.650.8% of flowCommon StockSEC:0001415889-25-008505:0
150,000 shares0Common StockSEC:0001415889-25-003232:0
26,183 shares@ US$2.6618.2% of flowCommon StockSEC:0001415889-24-022427:0
21,649 shares@ US$7.0640.9% of flowCommon StockSEC:0001415889-24-019970:0
40,000 shares0Common StockSEC:0001415889-24-008543:0
22,141 shares@ US$2.9317.7% of flowCommon StockSEC:0001209191-23-055527:0
75,000 shares0Common StockSEC:0001209191-23-047521:0
100,000 shares0Common StockSEC:0001209191-23-043306:0
7,500 shares@ US$3.407.4% of flowCommon StockSEC:0001209191-22-041835:0
Ideal exit: 7 Apr 2023 (T+270)
5,714 shares@ US$2.103.4% of flowCommon StockSEC:0001209191-22-040616:0
Ideal exit: 1 Apr 2023 (T+270)
2,500 shares@ US$9.790.019% mcap50.0% of flowCommon StockSEC:0001209191-21-038481:0
Ideal exit: 1 Mar 2022 (T+270)
2,500 shares@ US$9.795.9% of flowCommon StockSEC:0001209191-21-038481
Ideal exit: 1 Mar 2022 (T+270)
12 of 12 declarations
About Hayes Christopher G.
Christopher G. Hayes is the Chief Legal Officer at Verrica Pharmaceuticals Inc. He is responsible for managing legal issues and compliance for the company. Hayes plays a crucial role in protecting the company's legal interests.
